Fibrosis score consisting of four serum markers successfully predicts pathological fibrotic stages of chronic hepatitis B

2012 ◽  
Vol 43 (6) ◽  
pp. 596-604 ◽  
Author(s):  
Kenji Ikeda ◽  
Namiki Izumi ◽  
Eiji Tanaka ◽  
Hiroshi Yotsuyanagi ◽  
Yoshihisa Takahashi ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Serum Markers ◽  
Fibrosis Score

scholarly journals The analysis of the correlations between HBsAg quantitation level, virological markers and histopathological findings in patients with chronic hepatitis B

2021 ◽  
Author(s):  
Serkan Cerrah ◽  
Ozcan Deveci ◽  
Muhammed Bekçibaşı ◽  
Çiğdem Mermutluoğlu ◽  
Mustafa Kemal Çelen
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Hbv Dna ◽  
Index Score ◽  
Fibrosis Score ◽  
Histopathological Findings ◽  
Positive Correlation ◽  
Nucleic Acid Isolation ◽  
The Mean

In recent years, several studies suggested that HBsAg titers in blood samples obtained during Hepatitis B treatment could be used to estimate the treatment outcomes. The present study aims to discuss the correlation between HBsAg quantification levels and the virological, serological and histopathological findings in chronic hepatitis B patients.The study included chronic hepatitis B patients who underwent liver biopsy between 2011 and 2013 at Dicle University, Faculty of Medicine, Infectious Diseases and Clinical Microbiology Clinic.. The patient demographics were recorded (age, gender). Patient AST tests were conducted with the spectrophotometric method. After the DNAs were isolated with AmplipPrep Total Nucleic Acid Isolation Kit, DNA level was determined with the COBAS® Amplip / Cobas® Taqman® HBV test V2.0 for HBV. The patient HBV DNA levels were recorded as IU / ml. HBsAg quantitation was studied with the Access device and the Elisa method.The study was conducted with 53 patients. The mean patient age was 28,73 ± 8.15. Out of the 53 patients, 35 (66%) were male and 18 (34%) were female. The mean patient HBsAg quantitation was 631,42 ± 406.55, fibrosis score was 1,35 ± 0.87, ALT index score was 67,07 ± 53.37, and HAI index score was 4,54 ± 1.55. In the statistical analysis, it was determined that there were negative correlations between the HBsAg DNA level (R: -0,273, P: 0.048) and HBSAG quantitation (R: -0,273, P: 0.048), fibrosis score , ALT (R: -0,477, P: 0.001), and HAI index scores (R: -034, P: 0,013), while there was a positive correlation with the HBeAg positivity (R: 0.477, p: 0.001). There were negative correlations between the HBsAg quantitation level and virological (HBV DNA level), histopathological (fibrosis score, HAI index) findings and a positive correlation with serological (HBeAg positivity) findings. As HBsAg quantitation level increased, fibrosis score and HBV DNA level decreased.

The validity of serum markers for fibrosis staging in chronic hepatitis B and C

2014 ◽  
Vol 21 (12) ◽  
pp. 930-937 ◽  
Author(s):  
J. Li ◽  
S. C. Gordon ◽  
L. B. Rupp ◽  
T. Zhang ◽  
J. A. Boscarino ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Serum Markers ◽  
Fibrosis Staging

scholarly journals A novel HBsAg-based model for predicting significant liver fibrosis among Chinese patients with immune-tolerant phase chronic hepatitis B: a multicenter retrospective study

2021 ◽  
Vol 14 ◽  
pp. 175628482110106
Author(s):  
Da-Wu Zeng ◽  
Zu-Xiong Huang ◽  
Meng-Xin Lin ◽  
Na-Ling Kang ◽  
Xin Lin ◽  
...  
Keyword(s):  
Chronic Hepatitis ◽  
Liver Fibrosis ◽  
Hepatitis B ◽  
Chronic Hepatitis B ◽  
Predictive Value ◽  
Chinese Patients ◽  
Fibrosis Score ◽  
Non Invasive ◽  
Immune Tolerant ◽  
Significant Liver Fibrosis

Background: Hepatitis B e antigen (HBeAg)-positive chronic hepatitis B (CHB) in the immune-tolerant (IT) phase is significantly associated with high risk for hepatocellular carcinoma, suggesting requirement for antiviral therapy, particularly for those with histological liver injury. This study aimed to establish a non-invasive panel to assess significant liver fibrosis in IT chronic hepatitis B. Patients and methods: One hundred and thirteen IT-phase CHB patients were retrospectively recruited and divided into two histopathological groups according to their histological profiles: necroinflammatory score <4 (N <4)/fibrosis score ⩽1 (F0-1), and necroinflammatory score ⩾4 (N ⩾4)/fibrosis score ⩾2 (F2-4). Multivariate analysis was conducted to assess the predictive value of the non-invasive model for significant liver fibrosis. Results: IT-phase CHB patients with N <4/F0-1 had significantly higher HBsAg levels than those with N ⩾4/F2-4. The optimal HBsAg level of log 4.44 IU/mL for significant liver fibrosis (F ⩾2) gave an area under the curve (AUC) of 0.83, sensitivity of 81.1%, specificity of 81.6%, positive predictive value (PPV) of 68.2%, and negative predictive value (NPV) of 89.9%. An IT model with HBsAg and gamma glutamyl transpeptidase (GGT) in combination was established, and it had an AUC of 0.86, sensitivity of 86.5%, specificity of 81.6%, PPV of 69.6, NPV of 92.5, and accuracy of 83.2% to predict F ⩾2 in the IT-phase CHB patients. Notably, the IT model exhibited higher predictive value than the existing aspartate aminotransferase-to-platelet ratio index, Fibrosis-4 score, and GGT to platelet ratio. Conclusion: The established IT model combining HBsAg and GGT has good performance in predicting significant liver fibrosis in IT-phase CHB patients.

Sign in / Sign up

Export Citation Format

Share Document